Research Article

Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal

Hironobu Yamashita,1 Manisha Tripathi,1 Jerome Jourquin,1 Yoonseok Kam,2 Shanshan Liu,1 Brandy Weidow,1 and Vito Quaranta1

1 Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
2 Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Correspondence should be addressed to Vito Quaranta, vito.quaranta@vanderbilt.edu

Received 16 March 2010; Revised 11 June 2010; Accepted 2 July 2010

1. Introduction

Lysophosphatidic acid (LPA) is a phospholipid growth factor involved in a variety of physiological functions such as cellular proliferation, differentiation, migration, and survival [1, 2]. In addition, it has also been shown to play a role in pathological conditions like wound healing and tumorigenesis [3]. LPA is naturally produced by many cells, including platelets, fibroblasts, and adipocytes; therefore, body fluids like serum, saliva, and other follicular fluids are a rich source of LPA [4–7]. It is well established that LPA signals various events through its G protein-coupled receptors (GPCR), namely, LPA-1-4 [8].

During tumorigenesis, LPA is reportedly involved in both cell migration and invasion [9–12]. Many reports have shown that LPA plays an important role particularly in ovarian cancer, affecting various aspects of cancer development, including cellular proliferation, angiogenesis, migration, and survival [13, 14]. It has also been shown that increased levels of LPA are found in the plasma of ovarian cancer patients, compared to disease-free subjects [15]. Normal ovarian epithelial cells produce trace amounts of LPA, whereas ovarian cancer cells produce LPA in large amounts [16]. Similarly, in prostate cancer, LPA is reported to induce proliferation and survival of androgen-independent prostate cancer cells [17, 18]. In lung cancer, LPA has been shown to induce cellular migration [19]. LPA levels are also significantly increased in patients with myeloma, endometrial cancer, and cervical cancer [20, 21]. Autotaxin, a soluble exoenzyme upregulated in cancer cells that increases cell invasion, has been found to stimulate proliferation and motility of cancer cells through LPA production [22], whereas autotaxin-dependent motility is blocked in LPA-1 deficient fibroblasts [23].

Previously, we have shown that LPA causes dispersal of epithelial cell colonies [24]. Our report demonstrated...
stepwise upregulation of cell motility features after treatment of A431 cells with LPA. Specifically, we noted the following changes: stimulation of lamellipodia formation, downregulation of cell-cell adhesion, and enhanced migration of the cells. In continuing this line of research, we have thus hypothesized that LPA changes cell motility by somehow affecting the cell microenvironment. To begin to test this hypothesis, in this study we performed microarray analysis of A431 cancer cells treated with LPA or PBS (for control) to examine the changes in microenvironment-related genes. Interestingly, microarray results revealed that LPA upregulates several TGF-β1 target genes along with Ln-322, a major component of basement membrane. Several independent approaches also supported this finding.

2. Materials and Methods

2.1. Reagents. L-α-lysophosphatidic acid (oleoyl, LPA 18:1) was purchased from Avanti Polar Lipids (Alabaster, AL) and stored at −80°C. Polyclonal antibody (pAb) against phosphorylated Smad2 (Ser465/467), GAPDH, and monoclonal antibody (mAb) against Smad2/3 were purchased from Cell Signaling Technology (Danvers, MA), BD Biosciences (San Jose, CA), and Invitrogen (Carlsbad, CA), respectively. BM165 (mAb against human laminin α3 chain) was purchased from Life Technology Invtrogen (Carlsbad, CA). H-300 (pAb against human laminin β3 chain) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 2778, pAb against laminin γ2 chain was prepared in-house, as previously described in [25, 26]. MAb against β-actin was purchased from Sigma (St. Louis, MO). Anti-rabbit IgG or mouse IgG HRP-conjugated antibody was purchased from GE health care (Pittsburgh, PA).

2.2. Cell Culture. A431, a human epidermal squamous carcinoma cell line, was obtained from American Type Culture Collection (Manassas, VA), maintained in DMEM (Invitrogen), supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 2 mM L-glutamine, and kept in constant culture in a humidified incubator with 5% CO2 at 37°C.

2.3. Immunoblot Analysis. To examine phosphorylation of Smad2 and expression of Ln-332 chains by LPA, A431 cells were serum starved for 24 h and incubated with PBS or LPA (1–4 μM) for indicated periods of time. Cells were lysed and 100 μg of proteins were separated on 4–12% NuPAGE (Bis-Tris) gels under reducing conditions. 3T3NIH cell lysates were purchased from Cell Signaling and used as a positive control (for Smad2 phosphorylation). After separation, the same gel was transferred to a PVDF membrane and blocked with 5% skim milk in 1X TBS and 0.1% Tween 20. After the blocking step, pAb against phosphorylated Smad2 (pSmad2; Ser465/467), GAPDH, or mAb against Smad2/3 was added at the diluted ratio of 1:1000 and incubated at 4°C overnight. To check the expression of laminin α3, β3, and γ2 chains, BM165 mAb, H-300 pAb, or 2778 pAb was added at the diluted ratio of 1:1000, 1:200, 1:2000, respectively. MAb against β-actin was used as an internal control at the diluted ratio of 1:10000. Anti-rabbit IgG or mouse IgG HRP-conjugated antibody was used as a secondary antibody at the diluted ratio of 1:1000, 1:200, 1:2000, respectively. MAb against phosphorylated Smad2 (Ser465/467), GAPDH, or mAb against Smad2/3 was added at the blocking step, pAb against phosphorylated Smad2 (pSmad2; Ser465/467), GAPDH, and monoclonal antibody (mAb) against Smad2/3 were purchased from Cell Signaling Technology (Danvers, MA), BD Biosciences (San Jose, CA), and Invitrogen (Carlsbad, CA), respectively. BM165 (mAb against human laminin α3 chain) was purchased from Life Technology Invtrogen (Carlsbad, CA). H-300 (pAb against human laminin β3 chain) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 2778, pAb against laminin γ2 chain was prepared in-house, as previously described in [25, 26]. MAb against β-actin was purchased from Sigma (St. Louis, MO). Anti-rabbit IgG or mouse IgG HRP-conjugated antibody was purchased from GE health care (Pittsburgh, PA).

2.4. RNA Extraction and cDNA Synthesis. To detect the expression level of laminin α3, β3, and γ2 chains in A431 cells, total RNA was isolated from cells treated with PBS or 1-2 μM (1 μM for microarray analysis and 2 μM for real-time PCR) LPA using an RNAeasy kit (Qiagen, Germantown, MD). Total RNA digested with RQ RNase-free DNase I (Promega, Madison, WI) and OligoT primer (Roche, Madison, WI) was incubated for 10 min at 70°C, chilled on ice, and added to a 20 μl aliquot of a reaction mixture containing 4 μl of Transcriptor RT reaction buffer (Roche), 1 μl of 10 mM mixture of four dNTPs, and 1 μl of RNasin (Promega). In addition, 0.5 μl of Transcriptor Reverse Transcriptase (Roche, Madison, WI) was added and incubation continued for 1 h at 55°C. To stop the reaction, the reaction mixture was heated for 5 min at 85°C, and then chilled on ice. To remove RNA contamination in the reaction mixture, RNase H (Promega) was added and incubated for 30 min at 37°C. RNA integrity was determined by electrophoresis on a 1% agarose gel followed by visualization of intact 18S and 28S ribosomal RNA bands. RNA purity was measured using the A260/A280 ratio. To ensure that the optical density at A260 was in the linear range, various concentrations of RNA were plotted against absorbance.

2.5. cDNA Microarray Analysis. Microarray experiments were performed by the Vanderbilt University Medical Center Microarray Core using Affymetrix Human U133 plus 2.0 chips according to manufacturer’s instructions. Data were normalized using the Microarray Suite 5.0 algorithm. Due to our interest in particular genes, only some probe sets were analyzed, as shown in Table 1.

Table 1: Primers used for quantitative RT-PCR. For RT-PCR, we analyzed samples on an MiQ machine using a FastStart SYBR Green Master Mix, with the following primer sets.

| Gene    | Primer set          | Gene accession number |
|---------|---------------------|-----------------------|
| LAMA3   | 5’-GGCTCACCTGTATATTGGG | NM_000227             |
|         | 5’-ACAAGAAGCTGTTTTGTTG | NM_000228             |
| LAMB3   | 5’TGATGGAGAGGATGAAACAC | NM_005562             |
|         | 5’-GAAGCCCCAGAGGTGATAC | NM_002046             |
| LAMC2   | 5’-TGAGTGTCTGCGAGCAAG |NM_021130             |
| GAPDH   | 5’-ATGACATCGAAGGGTGTG | NM_000228             |
|         | 5’-CTGATGCAAAAATCTGGTGC | NM_005562             |
| PPIA    | 5’-CAAATGCTGGACCCACACA | NM_021130             |
|         | 5’-TGCCATCAAACCTACTGTC | NM_002046             |
Comparisons were made between RNA extracted from PBS-treated A431 cells and LPA-treated A431 cells (N = 2, in triplicate). Differences were examined with Student’s t-test statistics using SPSS, version 17 (Chicago, IL), with P values less than .05 accepted as significant.

2.6. Quantitative Real-Time PCR (RT-PCR). For RT-PCR, we analyzed samples on a MiQ machine (Bio-Rad Laboratories, Hercules, CA) using a FastStart SYBR Green Master Mix (Roche, Madison, WI). The following primer sets were used, as shown in Table 1: LAMA3 (forward): 5'-GGCTCA-CTCCTGATATTGTTG, LAMA3 (reverse): 5'-ACAGAGG- ACTGCTTTGTGTG, LAMB3 (forward): 5'-TGATGG-ACAGGATGAAAG, LAMB3 (reverse): 5'-GGAAGC-GTGAGCATCACTTG, LAMC2 (forward): 5'-GAAGCC-CAGAAGGTGTGAC, LAMC2 (reverse): 5'-GTTCTGGAGCAAAG, GAPDH (forward): 5'-ATGACA-TCAAGAAGGTTGTG, GAPDH (reverse): 5'-CTGTAGG-CAAAATTCGTGTGC, PPIA (forward): 5'-CAATAATGGCA- GACCCAACAC, PPIA (reverse): 5'-TGCCATCCACC- ACTCAGTC. These primers were designed by open-source Primer3 software (http://primer3.sourceforge.net).

Comparisons were made between RNA extracted from PBS-treated A431 cells and LPA-treated A431 cells (N = 2, in duplicate or triplicate). Differences were examined with Student’s t-test statistics using SPSS, version 17 (Chicago, IL), with P values less than .05 accepted as significant.

2.7. Cell Dispersal Assays. For dispersal assays, A431 cells were seeded at a density of 10⁴ cells/ml in 6-well plates and allowed to grow for 24 h. After formation of colonies, cells were cultured in serum-free DMEM for 24 h and then treated with PBS or LPA for 4 h. Microscopy was conducted using a Zeiss Axiovert 200 M microscope (Zeiss, Thornwood, NY) equipped with a temperature- and CO₂-controlled chamber (5 images per well, triplicate wells per treatment). Microscopy was under the control of OpenLab software (Improvision, Lexington, MA). To quantify cell behavior, we manually counted both the number of dispersed colonies and total colonies in each well of microplates. Differences were examined using two-way ANOVA with Bonferroni posttest using GraphPad Prism5 (La Jolla, CA), with values less than .05 accepted as significant. Data are presented as the mean ± standard deviation ratio (percentage) of dispersed colonies to total number of colonies imaged.

3. Results and Discussion

We previously reported that LPA dramatically induces A431 squamous carcinoma cell colony dispersal, accompanied by disruption of cell-cell contacts and individual cell migration [24]. Herein, we analyzed gene expression of A431 cancer cells treated with LPA in order to better understand how LPA functions during cell colony dispersal. To this end, we first recapitulated experiments from our previous studies, whereas A431 cells were serum starved for 24 h and then treated with LPA (1 μM) or PBS (control) for 12 h. After incubation, A431 cells were collected, and total RNA was extracted for cDNA microarray analysis. The RNA integrity was measured by the RNA integrity number (RIN) software algorithm designed to classify the eukaryotic total RNA, based on numbering from 1 to 10 (1 indicates the most degraded RNA profile, 10 indicates the most intact RNA). Electrophoresis of RNA in eukaryote total RNA Nano_DE11400902 resulted in an RNA integrity number (RIN) of 10.

Affymetrix cDNA microarray analysis was then performed to compare gene expression of A431 cells treated with either LPA or PBS. Due to our interest in particular genes, only some probe sets were processed and analyzed for this study. Of note, laminin α3 (LAMA3), β3 (LAMB3), and γ2 chains (LAMC2), all components of the Ln-332 heterotrimer, were significantly upregulated in LPA-treated samples (Figure 2; N = 2, in duplicate or triplicate; P = .022, .001, and .019, resp.). These results also revealed that several other genes involved in extracellular matrix were overexpressed in LPA-treated samples, including tenascin C, cysteine rich protein 61, thrombospondin-1, and serine peptidase inhibitor or plasminogen activator inhibitor-1 (data not shown). Interestingly, all of these genes have been shown to be TGF-β1 target genes [27–31].

The original observation on A431 colony dispersal has led us to further investigate cell phenotype epithelial-to-mesenchymal transition (EMT), which is reportedly induced by TGF-β1 in some cell systems and shows a disconnect between cells and dramatic changes in gene expression [32, 33]. TGF-β1 is a protein that controls cell proliferation and growth in many cells, stimulates production of extracellular matrix proteins, and induces EMT, which is accompanied
Among the overexpressed genes induced by LPA, we further investigated the three subcomponents of the intact Ln-332 molecule: α3 chain (LAM3), laminin β3 (LAMB3), and laminin γ2 chain (LAMC2) were significantly increased.

of heterotrimer α3β3γ2 [36, 37]. Ln-332 plays a significant role in controlling cell behavior, such as cell adhesion, migration, and spreading via cell surface receptors, including integrin α3β1 and integrin α6β4 [37, 38]. We performed quantitative RT-PCR analysis using laminin primer sets shown in Table 1 to confirm the upregulation of the three laminin genes upon LPA treatment of A431 cells. Real-time PCR analysis showed that LPA somewhat increased the expression of laminin α3, β3, and γ2 chains in A431 cells (by ∼2–2.5-fold compared to PBS controls), although not significantly (N = 3; P = .11, .08, and .13, resp.).
suggesting that LPA may also induce laminin $\alpha_3$, $\beta_3$, and $\gamma_2$ gene expression at the mRNA level (Figure 4). However, additional studies are needed to confirm this finding.

Furthermore, western blot analysis using antibodies against individual laminin $\alpha_3$, $\beta_3$, and $\gamma_2$ chains also showed that protein expression increased after LPA treating of A431 cells. Ln-332 $\alpha_3$ and $\beta_3$ chains were significantly enhanced in LPA-treated cells, whereas $\gamma_2$ chain was only somewhat increased using this method (Figures 5(a) and 5(b)). Collectively, these results suggest that Ln-332 heterotrimer expression is also elevated after LPA treatment. Interestingly, various cytokines, growth factors, and LPA have previously been shown to promote the synthesis of Ln-332 in human keratinocytes [39]. Taken together, three independent approaches show that Ln-332 is enhanced at the cDNA, mRNA, and protein levels, respectively.

The binding and their role of Ln-332 and integrin receptors have been intensely studied in various physiological events [43]. Ln-332 can promote strong cell adhesion by interacting with $\alpha_6\beta_4$ and intermediate filaments to form hemidesmosomes [37, 44–46] or can behave as a promigratory agent by binding to $\alpha_3\beta_1$ [47, 48]. These functions are observed in normal skin and wound healing, respectively [37, 44, 45, 48]. Collectively, these findings lead us to believe that LPA-inducible Ln-332 promotes A431 cell colony dispersal, presumably by interaction with cell surface receptor integrins $\alpha_3\beta_1$ or $\alpha_6\beta_4$. While the experimentation necessary to unravel this hypothesis is still in early stages, we have obtained some data that supports this idea. Using cell colony dispersal assays similar to our previous studies [24], we have found that adding anti-Ln-332 antibody to A431 cells almost completely blocked the dispersal of LPA-treated colonies (Figures 6(a) and 6(b)). These results strongly support a general role for Ln-332 in
Figure 6: Anti-Ln-332 antibody prevents A431 colony from dispersing by LPA treatment. Cell colony dispersal assays were performed similarly to our previous studies (serum-starved A431 cells for 24 h, treated with 2 μM LPA), with the addition of an anti-Ln-332 antibody (BM165). (a, b) We found that anti-Ln-332 antibody significantly blocked dispersal of LPA-treated colonies, compared to those colonies treated with LPA alone (N = 3; P < .05). LPA-treated A431 colony dispersal percentages in the absence (LPA) or presence of BM165 antibody (LPA + anti-Ln-332) are indicated as light-grey triangles or cross, respectively. These results strongly support a general role for Ln-332 in regulating the “LPA effect”. *P < .05, Two-way ANOVA (Bonferroni post test).

Figure 7: Hypothetical working model of LPA-induced A431 colony dispersal. We hypothesize that LPA induces Ln-332 expression via TGF-β1 pathway. In our working model, LPA binds to LPA receptors on the A431 cell surface and transactivates TGF-β1 type I receptor (TGFβR1), which phosphorylates receptor-regulated Smad (R-Smad), Smad2, and Smad3. These results are supported by other previous findings [36, 40, 41]. Another potential pathway may lead to the direct induction of phosphorylation of Smad2/3. Phosphorylated Smad2/3 forms complex with Smad4 and translocates into the nucleus [41]. Smad4 functions as a positive transcriptional regulator of Ln-332 [42]. Finally, LPA enhances Ln-332 expression to promote A431 colony dispersal.

regulating the “LPA effect”. In addition, preliminary studies have also shown that blocking antibodies against integrins α3 or β1, but not α6, remarkably reduced LPA-treated A431 colony dispersal (data not shown). Our findings are in line with previous studies by Salo et al. [49], which showed that antibodies blocking Ln-332 inhibit cell adhesion and migration, subsequently leading to reduced tumor growth and invasion in vivo. However, we plan to tackle additional studies in the future to further investigate the specific role of LPA in these data. Of note, Giannelli et al. previously demonstrated that Ln-332 and TGF-β1 cooperatively induce EMT in hepatocellular carcinoma [50].

In summary, we propose a working model of LPA-induced A431 colony dispersal (Figure 7). We hypothesize
that LPA induces Ln-332 expression via the TGF-β1 pathway. In our working model, LPA binds to LPA receptors on the A431 cell surface and transactivates TGF-β1 type I receptor (TGFβRI), which phosphorylates receptor-regulated Smad (R-Smad), Smad2, and Smad3 [36]. In addition, LPA potentially induces the direct phosphorylation of Smad2/3 via LPA receptors, or LPA-induced TGF-β1 signals activate phosphorylation of Smad2/3.

Phosphorylated Smad2/3 forms complex with Smad4 and translocates into the nucleus. It has been reported that smad4 functions as a positive transcriptional regulator of Lnc and translocates into the nucleus. It has been reported that LPA potentially enhances Ln-332 expression, leading to the promotion of A431 colony dispersal.

However, we recognize that our results could be the consequences of the activation of other pathways than TGF-β. In brief, we acknowledge that many previous studies have explored the downstream effectors of LPA, including RhoA, which is involved in contraction and cell rounding, Rac, which is involved in cell spreading and migration, Akt, which is involved in cell survival, and RAS, which is important in DNA synthesis and viability [51]. These multiple effects may explain why one compound, LPA, could have such a repertoire of cell responses.

4. Conclusions

Herein, we have reported that LPA induces TGF-β1 target gene expression including Ln-332 during LPA-induced A431 colony dispersal, and we conclude that Ln-332 plays a significant role in promoting colony dispersal and single-cell migration, at least for the A431 cell line.

Acknowledgments

The authors acknowledge the following funding sources for support of this paper: National Institutes of Health Grant CA47858-17A2 awarded to VQ and VICTR voucher support VR303 awarded to HY.

References

[1] E. J. van Corven, A. Groenink, K. Jalink, T. Eichholtz, and W. H. Moolenaar, “Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins,” Cell, vol. 59, no. 1, pp. 45–54, 1989.
[2] W. H. Moolenaar, L. A. van Meeteren, and B. N. G. Giepmans, “The ins and outs of lysophosphatidic acid signaling,” BioEssays, vol. 26, no. 8, pp. 870–881, 2004.
[3] S. Liu, M. Murph, N. Panupinthu, and G. B. Mills, “ATX-LPA receptor axis in inflammation and cancer,” Cell Cycle, vol. 8, no. 22, pp. 3695–3701, 2009.
[4] G. Tigyi, D. L. Dyer, and R. Miledi, “Lysophosphatidic acid possesses dual action in cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 5, pp. 1908–1912, 1994.
[5] F. Gaits, O. Fourcade, F. Le Balle et al., “Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis,” FEBS Letters, vol. 410, no. 1, pp. 54–58, 1997.
[6] C. Pages, A. Girard, O. Jeanneton et al., “LPA as a paracrine mediator of adipocyte growth and function,” Annals of the New York Academy of Sciences, vol. 905, pp. 159–164, 2000.
[7] T. Sano, D. Baker, T. Virag et al., “Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21197–21206, 2002.
[8] N. Fukushima and J. Chun, “The LPA receptors,” Prostaglandins and Other Lipid Mediators, vol. 64, no. 1–4, pp. 21–32, 2001.
[9] F. Imamura, T. Horai, M. Mukai, K. Shinkai, M. Sawada, and H. Akedo, “Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D,” Biochemical and Biophysical Research Communications, vol. 193, no. 2, pp. 497–503, 1993.
[10] D. A. Fishman, Y. Liu, S. M. Ellerbroek, and M. S. Stack, “Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells,” Cancer Research, vol. 61, no. 7, pp. 3194–3199, 2001.
[11] Y. Zheng, Y. Kong, and E. J. Goetzl, “Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a matrigel model basement membrane,” The Journal of Immunology, vol. 166, no. 4, pp. 2317–2322, 2001.
[12] A. Gschwind, S. Hart, O. M. Fischer, and A. Ullrich, “TACE cleavage of proangiogenin regulates GPCR-induced proliferation and motility of cancer cells,” The EMBO Journal, vol. 22, no. 10, pp. 2411–2421, 2003.
[13] G. B. Mills, A. Eder, X. Fang et al., “Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer,” Cancer Treatment and Research, vol. 107, pp. 259–283, 2002.
[14] Y. Xu, Y. J. Xiao, K. Zhu et al., “Unfolding the pathophysiolog-ical role of bioactive lysophospholipids,” Current Drug Targets. Immune, Endocrine & Metabolic Disorders, vol. 3, no. 1, pp. 23–32, 2003.
[15] J. A. Roberts, “Searching for a biomarker for ovarian cancer,” JAMA, vol. 280, no. 8, p. 739, 1998.
[16] X. Fang, D. Gaudette, T. Furui et al., “Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer,” Annals of the New York Academy of Sciences, vol. 905, pp. 188–208, 2000.
[17] P. F. Kue, J. S. Taub, L. B. Harrington, R. D. Polakiewicz, A. Ullrich, and Y. Daaka, “Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells,” International Journal of Cancer, vol. 102, no. 6, pp. 572–579, 2002.
[18] Y. Daaka, “Mitogenic action of LPA in prostate,” Biochimica et Biophysica Acta, vol. 1582, no. 1–3, pp. 265–269, 2002.
[19] T. Kusama, M. Mukai, M. Ayaki et al., “Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors,” International Journal of Oncology, vol. 23, no. 4, pp. 1173–1178, 2003.
[20] T. Sasagawa, M. Okita, J. Murakami, T. Kato, and A. Watanabe, “Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells,” Current Drug Targets. Immunology, vol. 2, no. 3, pp. 199–208, 2002.
[21] Y. Xu, Z. Shen, D. W. Wiper et al., “Lysophosphatidic acid-induced RhoA activation and tumor cell invasion by G proteins,” Current Drug Targets. Immune, Endocrine & Metabolic Disorders, vol. 3, no. 1, pp. 23–32, 2003.
[23] K. Hama, J. Aoki, M. Fukaya et al., “Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1,” *Journal of Biological Chemistry*, vol. 279, no. 17, pp. 17634–17639, 2004.

[24] J. Jourquin, N. Yang, Y. Kam, C. Guess, and V. Quaranita, “Dispersal of epithelial cell colonies by lysophosphatidic acid (LPA),” *Journal of Cellular Physiology*, vol. 206, no. 2, pp. 337–346, 2006.

[25] S. Schenk, E. Hintermann, M. Bilban et al., “Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution,” *Journal of Cell Biology*, vol. 161, no. 1, pp. 197–209, 2003.

[26] N. Koshikawa, S. Schenk, G. Moecckel et al., “Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology,” *The FASEB Journal*, vol. 18, no. 2, pp. 364–366, 2004.

[27] M. Jinnin, H. Ihn, Y. Asano, K. Yamane, M. Trojanowska, and K. Tamaki, “Tenascin-C upregulation by transforming growth factor-β in human dermal fibroblasts involves Sma3δ, Sp1, and Et1,” *Oncogene*, vol. 23, no. 9, pp. 1656–1667, 2004.

[28] C. P. Denton and D. J. Abraham, “Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis,” *Current Opinion in Rheumatology*, vol. 13, no. 6, pp. 505–511, 2001.

[29] S. Dennler, S. Itoh, D. Vivien, P. T. Dijke, S. Huet, and J.-M. Gauthier, “Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,” *The EMBO Journal*, vol. 17, no. 11, pp. 3091–3100, 1998.

[30] F. C. McGillicuddy, D. O’Toole, J. A. Hickey, W. M. Galagher, K. A. Dawson, and A. K. Keenan, “TGF-β1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by flavustatin in human coronary artery smooth muscle cells,” *Vascular Pharmacology*, vol. 44, no. 6, pp. 469–475, 2006.

[31] M. M. Chen, A. Lam, J. A. Abraham, G. E. Schreiner, and A. H. Joly, “CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis,” *Journal of Molecular and Cellular Cardiology*, vol. 32, no. 10, pp. 1805–1819, 2000.

[32] J. M. Lee, S. Dedhar, R. Kalluri, and E. W. Thompson, “The epithelial-mesenchymal transition: new insights in signaling, development, and disease,” *Journal of Cell Biology*, vol. 172, no. 7, pp. 973–981, 2006.

[33] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” *Cell*, vol. 139, no. 5, pp. 871–890, 2009.

[34] Y. Shi and J. Massague, “Mechanisms of TGF-β signaling from cell membrane to the nucleus,” *Cell*, vol. 113, no. 6, pp. 685–700, 2003.

[35] B. Sauer, R. Vogler, K. Zimmermann et al., “Lysophosphatidic acid interacts with transforming growth factor-β signaling to mediate keratinocyte growth arrest and chemotaxis,” *Journal of Investigative Dermatology*, vol. 123, no. 5, pp. 840–849, 2004.

[36] E. S. Jeon, H. J. Moon, M. J. Lee, et al., “Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells,” *Stem Cells*, vol. 26, no. 3, pp. 789–797, 2008.

[37] W. G. Carter, M. C. Ryan, and P. J. Gahr, “Epiligrin, a new cell adhesion ligand for integrin α6β1 in epithelial basement membranes,” *Cell*, vol. 65, no. 4, pp. 599–610, 1991.

[38] C. M. Niessen, F. Hogervorst, L. H. Jaspers et al., “The α6β4 integrin is a receptor for both laminin and kalinin,” *Experimental Cell Research*, vol. 211, no. 2, pp. 360–367, 1994.

[39] S. Amano, N. Akatsu, Y. Ogura, and T. Nishiyama, “Increase of laminin 5 synthesis in human keratinocytes by acute wound fluid, inflammatory cytokines and growth factors, and lysophospholipids,” *British Journal of Dermatology*, vol. 151, no. 5, pp. 961–970, 2004.

[40] B. Sauer, R. Vogler, K. Zimmermann, et al., “Lysophosphatidic acid interacts with transforming growth factor-β signaling to mediate keratinocyte growth arrest and chemotaxis,” *Journal of Investigative Dermatology*, vol. 123, no. 5, pp. 840–849, 2004.

[41] J. Massagué, “TGF-β signal transduction,” *Annual Review of Biochemistry*, vol. 67, pp. 753–791, 1998.

[42] M. Zapatka, D. Zboralski, Y. Radacz et al., “Basement membrane component laminin-5 is a target of the tumor suppressor Smad4,” *Oncogene*, vol. 26, no. 10, pp. 1417–1427, 2007.

[43] E. Hintermann and V. Quaranita, “Epithelial cell motility on laminin-5: regulation by matrix assembly, proteolysis, integrins and erbB receptors,” *Matrix Biology*, vol. 23, no. 2, pp. 75–85, 2004.

[44] L. Borradori, S. Chavanas, R. Q. J. Schaapveld et al., “Role of the bullous pemphigoid antigen 180 (BP180) in the assembly of hemidesmosomes and cell adhesion—expression of BP180 in generalized atrophic benign epidermolysis bullosa keratinoctyes,” *Experimental Cell Research*, vol. 239, no. 2, pp. 463–476, 1998.

[45] J. C. R. Jones, S. B. Hopkinson, and L. E. Goldfinger, “Structure and assembly of hemidesmosomes,” *BioEssays*, vol. 20, no. 6, pp. 488–494, 1998.

[46] Y. Hirako and K. Owaribe, “Hemidesmosomes and their unique transmembrane protein BP180,” *Microscopy Research and Technique*, vol. 43, no. 3, pp. 207–217, 1998.

[47] K. Zhang and R. H. Kramer, “Laminin 5 deposition promotes keratinocyte motility,” *Experimental Cell Research*, vol. 227, no. 2, pp. 309–322, 1996.

[48] B. P. Nguyen, X.-D. Ren, M. A. Schwartz, and W. G. Carter, “Ligation of integrin α3β1 by Laminin 5 at the wound edge activates Rho-dependent adhesion of leading keratinoctyes on collagen,” *The Journal of Biological Chemistry*, vol. 276, no. 47, pp. 43860–43870, 2001.

[49] S. Salo, A. Boutaud, A. J. Hansen et al., “Antibodies blocking adhesion and matrix binding domains of laminin-332 inhibit tumor growth and metastasis in vivo,” *International Journal of Cancer*, vol. 125, no. 8, pp. 1814–1825, 2009.

[50] G. Giannelli, C. Bergamini, E. Fransvea, C. Sgarra, and S. Antonaci, “Laminin-5 with transforming growth factor-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma,” *Gastroenterology*, vol. 129, no. 5, pp. 1375–1383, 2005.

[51] G. B. Mills and W. H. Moolenaar, “The emerging role of lysophosphatidic acid in cancer,” *Nature Reviews Cancer*, vol. 3, no. 8, pp. 582–591, 2003.